<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="against the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the" exact="treatment" post="of COVID-19 patients is available, nor is there evidence"/>
 <result pre="targets in the JAK-STAT pathway that can be manipulated in" exact="treatment" post="for coronaviruses and it is evident that IL-1 is"/>
 <result pre="currently no evidence for a role of these drugs in" exact="treatment" post="of COVID-19. Conclusion The COVID-19 pandemic has led to"/>
 <result pre="Conclusion The COVID-19 pandemic has led to challenging decision-making about" exact="treatment" post="of critically unwell patients. Low-dose prednisolone and tacrolimus may"/>
 <result pre="put them at risk of increased morbidity/mortality associated with COVID-19" exact="infection" post="and 2) those that may be used to treat"/>
 <result pre="woman with stage IIIA breast cancer from 1999 reported that" exact="diagnosis" post="of coronavirus following treatment for cancer using a high-dose"/>
 <result pre="breast cancer from 1999 reported that diagnosis of coronavirus following" exact="treatment" post="for cancer using a high-dose chemotherapy regimen and autologous"/>
 <result pre="and 6-thioguanine (6TG) have been used in cancer chemotherapy for" exact="treatment" post="of acute lymphoblastic or myeloblastic leukaemia and were found"/>
 <result pre="strong evidence for or against the use of ibuprofen for" exact="treatment" post="of COVID-19 specifically. One study did however link SARS-CoV"/>
 <result pre="two doses of the corticosteroid in the acute phase of" exact="infection" post="may effectively alleviate early pro-inflammatory response, but prolonged administration"/>
 <result pre="A separate Chinese study, which separated SARS-CoV patients into 4" exact="treatment" post="groups, identified early high-dose steroids in combination with a"/>
 <result pre="evidence for or against the use of NSAIDs in the" exact="treatment" post="of COVID-19 patients, though there appears to be some"/>
 <result pre="be some evidence that corticosteroids may be beneficial in the" exact="treatment" post="of SARS-CoV. However, it is important to note this"/>
 <result pre="SARS coronavirus, suggesting that TNFa inhibitors could be a potential" exact="treatment" post="for the acute respiratory disease syndrome caused by coronavirus"/>
 <result pre="IL6 an actor in the pathogenetic mechanisms of the coronavirus" exact="infection" post="COVID-19 induces a pro-inflammatory generation and secretion of cytokines"/>
 <result pre="provide relief in both systemic inflammation and fever occurring after" exact="infection" post="[24]. Cytokine profiles in patients diagnosed with SARS showed"/>
 <result pre="of IL-6 and on days 2 and 3 after SARS-CoV" exact="infection" post="was closely linked to the virus replication and disease"/>
 <result pre="tissue damage in SARS patients [33]. In patients with a" exact="diagnosis" post="of SARS-associated coronavirus infection, there were no significant differences"/>
 <result pre="that an interferon-gamma-related cytokine storm was induced post SARS coronavirus" exact="infection" post="[35]. Eight patients with SARS [36] were treated with"/>
 <result pre="Potential targets for therapeutic intervention related to IL6 regulation during" exact="infection" post="ADAM-17 regulates IL-6 class switching as a mediator between"/>
 <result pre="ability of the virus to circumvent innate immunity. The COVID-19" exact="infection" post="has also been observed to induce pro-inflammatory cytokine generation"/>
 <result pre="pandemic progresses and further clinical data becomes available. In vitro" exact="treatment" post="with glycopyrronium, formoterol and budesonide exerted additive inhibitory effects"/>
 <result pre="malignant cells in cancer. JAK inhibitors are used in the" exact="treatment" post="of cancer and inflammatory diseases such as rheumatoid arthritis"/>
 <result pre="by the European Medicines Agency in February 2017 for the" exact="treatment" post="of moderate-to-severe active rheumatoid arthritis in adults with an"/>
 <result pre="[46]. Therefore, IRE1α may be a novel target against coronavirus" exact="infection" post="requiring further exploration. Tylophorine-based compounds Tylophorine-based compounds are isolated"/>
 <result pre="alternative dominant NF-κB activation mediated by JAK2. Therefore, the combination" exact="treatment" post="for the inhibition of coronavirus per se, e.g. viral"/>
 <result pre="in the JAK-STAT pathway that can be manipulated in the" exact="treatment" post="for coronaviruses, they are all in early stages and"/>
 <result pre="the first 12, 7 and 5 days following onset of" exact="infection" post="[17]. Those patients with more severe disease were treated"/>
 <result pre="of pro-inflammatory cytokines such as IL-1 may be a beneficial" exact="treatment" post="strategy for treatment of SARS [50]. A third study,"/>
 <result pre="such as IL-1 may be a beneficial treatment strategy for" exact="treatment" post="of SARS [50]. A third study, which measured serum"/>
 <result pre="severe SARS and convalescent SARS patients suggested that longer term" exact="treatment" post="(over a period of 7-10 days) with low-dose steroids"/>
 <result pre="evidence for an established role for IL-1 blockers in the" exact="treatment" post="of COVID-19 in humans. The literature did, however, suggest"/>
 <result pre="had not been tested in a clinical setting for the" exact="treatment" post="of MERS-CoV. Al Ghamdi et al [59], presented an"/>
 <result pre="appeared to suggest a potential role for tacrolimus in the" exact="treatment" post="of human coronaviruses. In a case study of two"/>
 <result pre="recovery whilst the other patient (who was not on this" exact="treatment" post="regimen) succumbed to the infection [60]. The patient who"/>
 <result pre="(who was not on this treatment regimen) succumbed to the" exact="infection" post="[60]. The patient who eventually made a full recovery"/>
 <result pre="role of FK506 (tacrolimus) as a potent antiviral in the" exact="treatment" post="of human coronaviruses. It is important to note, however,"/>
 <result pre="progressing SARS-CoV-2 pandemic has led to challenging decision-making about the" exact="treatment" post="of critically unwell patients with the novel viral infection."/>
 <result pre="Country of study Year Summary of results [1] The differential" exact="diagnosis" post="of pulmonary infiltrates in cancer patients during the outbreak"/>
 <result pre="the clinical scenario of pulmonary infiltrates in cancer patients. Active" exact="treatment" post="against the infection and patient surveillance should be initiated"/>
 <result pre="of pulmonary infiltrates in cancer patients. Active treatment against the" exact="infection" post="and patient surveillance should be initiated if infectious disease"/>
 <result pre="limited benefits of adjuvant chemotherapy, the intensity and duration of" exact="treatment" post="can be reduced. In the face of patients with"/>
 <result pre="(HCoV-OC43). During chemotherapy the child had a persistent HCoV-OC43 respiratory" exact="infection" post="and later developed progressive encephalitis. Cerebrospinal fluid was negative"/>
 <result pre="play an etiologic role in febrile neutropenia in children receiving" exact="treatment" post="for a malignancy. [7] An Overview of Severe Acute"/>
 <result pre="a useful viral entry inhibitor for SARS treatment. [12] Alternative" exact="screening" post="approaches for discovery of Middle East respiratory syndrome coronavirus"/>
 <result pre="al Brazil 2014 Paediatric patients with cancer and acute respiratory" exact="infection" post="[14] and/or fever. Coronavirus was identified in 6.8% in"/>
 <result pre="the importance of these pathogens in the studied population. The" exact="prevalence" post="of respiratory viruses was relevant in the infectious episode,"/>
 <result pre="with cancer and ARIs. The link of whether severe acute" exact="infection" post="was directly related to the type of cancer or"/>
 <result pre="and 6-thioguanine (6TG) have been used in cancer chemotherapy for" exact="treatment" post="of acute lymphoblastic or myeloblastic leukaemia and were found"/>
 <result pre="the spread of virus. CBA administration may bring the viral" exact="infection" post="under control before glycan deletions occur and the immune"/>
 <result pre="report: coronavirus in woman with stage III breast cancer following" exact="treatment" post="with hig-dose chemotherapy and autologous bone marrow and stem"/>
 <result pre="permeability. ACE2-associated lung injury has been suggested in SARS- CoV" exact="infection" post="From reading this article the following article was then"/>
 <result pre="data suggest that ACE2 expression is increased in diabetes and" exact="treatment" post="with ACE inhibitors and ARBs increases ACE2 expression. Consequently,"/>
 <result pre="ACE2 expression. Consequently, the increased expression of ACE2 would facilitate" exact="infection" post="with COVID-19.The authors therefore hypothesise that diabetes and hypertension"/>
 <result pre="infection with COVID-19.The authors therefore hypothesise that diabetes and hypertension" exact="treatment" post="with ACE2-stimulating drugs increases the risk of developing severe"/>
 <result pre="the risk of developing severe and fatal COVID-19. [25] Drug" exact="treatment" post="options for the 2019-new coronavirus (2019- nCoV) Lu China"/>
 <result pre="clinical and laboratory manifestations. Lam, Chan, Wong China 2004 Corticosteroid" exact="treatment" post="reduced interleukin 8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and"/>
 <result pre="IFN-γ-inducible protein-10 (IP-10) concentrations from 5 - 8 days after" exact="treatment" post="in SARS patients. These were all inflammatory markers which"/>
 <result pre="dexamethasone as a model for SARS.Goal to define whether corticosteroid" exact="treatment" post="altered immunity and lung inflammatory response at cytokine level"/>
 <result pre="cytokine level and how changes correlated with pig lung lesions.Confirmed" exact="infection" post="model applicable and resembled SARS.Treatment with dexamethasone suppressed early"/>
 <result pre="later on in disease. Suggests may decrease inflammation at early" exact="infection" post="stage but not later.Results also suggest that dexamethasone induced"/>
 <result pre="onset of lung lesions but increases of IL-6 at later" exact="infection" post="stage may contribute to severity of lung lesions (mimicking"/>
 <result pre="1 or 2 doses of dexamethasone in acute phase of" exact="infection" post="may effectively alleviate early pro-inflammatory response, but prolonged DEX"/>
 <result pre="alleviate pulmonary inflammatory reaction. [32] Overview of antiviral and anti-inflammatory" exact="treatment" post="for severe acute respiratory syndrome. Chihrin S, Loutfy MR"/>
 <result pre="to corticosteroid use centred around use of corticosteroid use in" exact="treatment" post="of acute respiratory distress syndrome- concern that corticosteroid treatment"/>
 <result pre="in treatment of acute respiratory distress syndrome- concern that corticosteroid" exact="treatment" post="may weaken immune response and promote viral rebound. Reports"/>
 <result pre="Germany (needs to be purchased) 2005 Investigated influence of SARS-CoV" exact="infection" post="on CXCL8 and CXCL10 in human intestinal epithelial cells.High"/>
 <result pre="concentrations from 5-8 days after treatment. [35] Description and clinical" exact="treatment" post="of an early outbreak of severe acute respiratory syndrome"/>
 <result pre="mediator of the severe immune-based pulmonary injury which can follow" exact="infection" post="with H5N1 influenza and SARS coronavirus. In humans, anti-TNF"/>
 <result pre="therapy utilising etanercept has been reported to be beneficial for" exact="treatment" post="of the non-infectious idiopathic pneumonia syndrome which can follow"/>
 <result pre="of ameliorating the severe alveolar damage which can occur following" exact="infection" post="with these agents. [37] Anti-TNF alpha therapy does not"/>
 <result pre="of severe COVID‐19 in the adult patients, and their combined" exact="detection" post="had the highest specificity and sensitivity for early prediction"/>
 <result pre="S. China 2020 29 patients with 2019-ncov admitted to the" exact="isolation" post="ward of Tongji hospital ( mild (15 cases), severe"/>
 <result pre="novel antiviral drug discovery that would regulate host reactivity to" exact="infection" post="and thereby limit or prevent fatal outcomes. [43] Extraordinary"/>
 <result pre="(IL)-6 and IL-8, at the transcriptional level. IBV modulates the" exact="infection" post="by inducing the expression of dual-specificity phosphatase 1 (DUSP1),"/>
 <result pre="of IL-6 and on days 2 and 3 after SARS-CoV" exact="infection" post="was closely linked to the virus replication and disease"/>
 <result pre="in the lung cells. [49] Cytokine regulation in SARS coronavirus" exact="infection" post="compared to other respiratory virus infections. Okabayashi T; Kariwa"/>
 <result pre="2006 They compared the cytokine profile in Caco2 cells after" exact="infection" post="of SARS coronavirus (SARS-CoV) with other respiratory viruses including"/>
 <result pre="(IFN) system (production and response) was not suppressed by SARS-CoV" exact="infection" post="SARS-CoV and RSV induced high levels of IL-6 and"/>
 <result pre="WC; Yang PC. Singapore 2005 Fourteen hospitalised patients with a" exact="diagnosis" post="of SARS-associated coronavirus infection. There were no significant differences"/>
 <result pre="MCP-1 and IP-10 concentrations from 5 to 8 days after" exact="treatment" post="(all p &amp;lt; 0.001). [55] Dynamic changes and the"/>
 <result pre="of study Year Summary of results [57] Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory disease Richardson et al England"/>
 <result pre="This study uses endoplasmic reticulum stress and IFN-I production after" exact="infection" post="with transmissible gastroenteritis virus (TGEV) to understand how coronavirus-elicited"/>
 <result pre="either one alone and constitutes a feasible approach for the" exact="treatment" post="of SARS-CoV or MERS-CoV [61] Severe Acute Respiratory Syndrome"/>
 <result pre="[64] Role of the inflammasome-related cytokines Il-1 and Il-18 during" exact="infection" post="with murine coronavirus. Zalinger, Elliott and Weiss USA 2017"/>
 <result pre="promote cell mediated and/or humoral immunity.Similarly to avian flu, SARS" exact="infection" post="induced similar pro-inflammatory cytokine pattern and might contribute to"/>
 <result pre="to the severe nature of the virus.Clinical evidence of SARS" exact="treatment" post="by corticosteroids where levels of IL-1beta reduced after administration-"/>
 <result pre="inflammatory cytokines such as IL-1 may be beneficial strategy for" exact="treatment" post="of SARS. [54] Analysis of serum cytokines in patients"/>
 <result pre="and therefore results consistent with reports that only long term" exact="treatment" post="(7-10 days) with a steroid can alter serum cytokine"/>
 <result pre="Kong 2004 Known that over-expression of IL-1beta hallmark of SARS" exact="infection" post="probably through activation of transcription factor nuclear factor, activator"/>
 <result pre="mM. This drug may provide an alternative to ribavirin for" exact="treatment" post="of MERS-CoV. In conclusion, IFN-b, MPA or a combination"/>
 <result pre="a combination of the two may be beneficial in the" exact="treatment" post="of MERS-CoV or as a post-exposure intervention in high-risk"/>
 <result pre="be given orally.Interferon-b1b with mycophenolic acid should be considered in" exact="treatment" post="trials of MERS. [72] High-Throughput Screening and Identification of"/>
 <result pre="for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV)" exact="infection" post="at a coronavirus referral center in the Kingdom of"/>
 <result pre="who received mycophenolate mofetil survived. The authors concluded that whilst" exact="treatment" post="with beta interferon and mycophenolate mofetil predicted survival (in"/>
 <result pre="[75] Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERSCoV" exact="infection" post="in a nonhuman primate model of common marmoset Chan"/>
 <result pre="virus titers in placebo-treated, infected mice. [77] A review of" exact="treatment" post="modalities for Middle East Respiratory Syndrome Mo and Fisher"/>
 <result pre="therefore state that MPA should be used with caution for" exact="treatment" post="of MERS-CoV. The EC50 is the concentration of a"/>
 <result pre="involvement of FK506-binding proteins in viral replication. [82] MERS CoV" exact="infection" post="in two renal transplant recipients: Case report Al Ghamdi"/>
 <result pre="pneumonia following autologous bone marrow transplantation for breast cancerChest1999115390190510.1378/chest.115.3.90110084516 7.LaFeminaRLAlternative" exact="screening" post="approaches for discovery of middle east respiratory syndrome coronavirus"/>
 <result pre="activity against SARS coronavirusAntivir therapy200611810211030 14.ChihrinSLoutfyMROverview of antiviral and anti-inflammatory" exact="treatment" post="for severe acute respiratory syndromeExpert Rev Anti Infect Ther20053225126210.1586/14787210.3.2.25115918782"/>
 <result pre="for severe acute respiratory syndromeJ Virol20088294420442810.1128/JVI.02190-0718287230 19.ZhaoZZhangFXuMet al.Description and clinical" exact="treatment" post="of an early outbreak of severe acute respiratory syndrome"/>
 <result pre="cellular transcription factor NF-kappaBVirology2007365232433510.1016/j.virol.2007.04.00917490702 26.OkabayashiTKariwaHYokotaS-Iet al.Cytokine regulation in SARS coronavirus" exact="infection" post="compared to other respiratory virus infectionsJ Med Virol200678441742410.1002/jmv.2055616482545 27.TsengC-TKPerroneLAZhuHet"/>
 <result pre="28.ChanJFYaoYYeungMLet al.Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ Infect"/>
 <result pre="autoimmune diseaseCurr Opin Pharmacol201212446447010.1016/j.coph.2012.06.00822819198 44.AgencyEMOlumiant (baricitinib)2019[https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant] 45.RichardsonPGriffinITuckerCet al.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet202039510223e30e110.1016/S0140-6736(20)30304-432032529 46.MaYWangCXueMet al.The coronavirus transmissible"/>
 <result pre="the emerging Middle East respiratory syndrome coronavirusJ Infect201367660661610.1016/j.jinf.2013.09.02924096239 56.ShenLNiuJWangCet al.High-throughput" exact="screening" post="and identification of potent broad-spectrum inhibitors of coronavirusesJ Virol2019931210.1128/JVI.00023-19"/>
 <result pre="coronavirus in cell-based assaysJ Gen Virol201495Pt 357157710.1099/vir.0.061911-024323636 58.MoYFisherDA review of" exact="treatment" post="modalities for Middle East Respiratory SyndromeJ Antimicrob Chemother201671123340335010.1093/jac/dkw33827585965 59.Al"/>
 <result pre="for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV)" exact="infection" post="at a coronavirus referral center in the Kingdom of"/>
 <result pre="the Kingdom of Saudi ArabiaBMC Infect Dis201616117410.1186/s12879-016-1492-427097824 60.AlGhamdiMMushtaqFAwnNet al.MERS CoV" exact="infection" post="in two renal transplant recipients: case reportAm J Transplant20151541101110410.1111/ajt.1308525716741"/>
 <result pre="cyclosporine A-derivatives including AlisporivirVirus Res2014184445310.1016/j.virusres.2014.02.01024566223 References References 1.ZhuWJWangJHeXHet al.[The differential" exact="diagnosis" post="of pulmonary infiltrates in cancer patients during the outbreak"/>
 <result pre="undergoing hematopoietic cell transplantFront Microbiol20189309710.3389/fmicb.2018.0309730619176 9.MilanoFCampbellAPGuthrieKAet al.Human rhinovirus and coronavirus" exact="detection" post="among allogeneic hematopoietic stem cell transplantation recipientsBlood2010115102088209410.1182/blood-2009-09-24415220042728 10.OgimiCWaghmareAAKuypersJMet al.Clinical"/>
 <result pre="anti-SARS coronavirus chemistry, biology and chemotherapyAnnu Rep Med Chem20074118319619649165 12.LaFeminaRLAlternative" exact="screening" post="approaches for discovery of middle east respiratory syndrome coronavirus"/>
 <result pre="mellitus at increased risk for COVID-19 infection?Lancet Respir Med202010.1016/S2213-2600(20)30116-832171062 25.LuHDrug" exact="treatment" post="options for the 2019-new coronavirus (2019-nCoV)Biosci Trends202010.5582/bst.2020.01020 26.LamCWKChanMHMWongCKSevere acute"/>
 <result pre="it]Zhonghua nei ke za zhi2005441289089316409721 32.ChihrinSLoutfyMROverview of antiviral and anti-inflammatory" exact="treatment" post="for severe acute respiratory syndromeExpert Rev Anti-infect Ther20053225126210.1586/14787210.3.2.25115918782 33.CinatlJMichaelisMMorgensternBet"/>
 <result pre="severe acute respiratory syndromeClin Exp Immunol200413619510310.1111/j.1365-2249.2004.02415.x15030519 35.ZhaoZZhangFXuMet al.Description and clinical" exact="treatment" post="of an early outbreak of severe acute respiratory syndrome"/>
 <result pre="cellular transcription factor NF-kappaBVirology2007365232433510.1016/j.virol.2007.04.00917490702 49.OkabayashiTKariwaHYokotaS-Iet al.Cytokine regulation in SARS coronavirus" exact="infection" post="compared to other respiratory virus infectionsJ Med Virol200678441742410.1002/jmv.2055616482545 50.ShengW-HChiangB-LChangS-Cet"/>
 <result pre="children with severe acute respiratory syndromePediatrics2004113e7e1410.1542/peds.113.1.e714702488 57.RichardsonPGriffinITuckerCet al.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet202039510223e30e110.1016/S0140-6736(20)30304-432032529 58.ChenNZhouMDongXet al.Epidemiological and clinical"/>
 <result pre="chemokinesVirology2007369228829810.1016/j.virol.2007.07.03017804032 64.ZalingerZBElliottRWeissSRRole of the inflammasome-related cytokines Il-1 and Il-18 during" exact="infection" post="with murine coronavirusJ Neurovirol201723684585410.1007/s13365-017-0574-428895072 65.ChenIYMoriyamaMChangM-Fet al.Severe acute respiratory syndrome"/>
 <result pre="the emerging Middle East respiratory syndrome coronavirusJ Infect201367660661610.1016/j.jinf.2013.09.02924096239 72.ShenLNiuJWangCet al.High-throughput" exact="screening" post="and identification of potent broad-spectrum inhibitors of coronavirusesJ Virol2019931210.1128/JVI.00023-19"/>
 <result pre="for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV)" exact="infection" post="at a coronavirus referral center in the Kingdom of"/>
 <result pre="75.ChanJFYaoYYeungMLet al.Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ Infect"/>
 <result pre="by IMP dehydrogenase inhibitors, including ribavirinAntiviral Res2006711536310.1016/j.antiviral.2006.03.00116621037 77.MoYFisherDA review of" exact="treatment" post="modalities for Middle East Respiratory SyndromeJ Antimicrob Chemother201671123340335010.1093/jac/dkw33827585965 78.Al-TawfiqJAMemishZAUpdate"/>
 <result pre="is inhibited by the drug FK506Virus Res2012165111211710.1016/j.virusres.2012.02.00222349148 82.AlGhamdiMMushtaqFAwnNet al.MERS CoV" exact="infection" post="in two renal transplant recipients: case reportAm J Transplant20151541101110410.1111/ajt.1308525716741"/>
</results>
